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Abstract
Clostridial bacteraemia is usually associated with substantial morbidity and mortality in cancer patients. However, clinical characteristics and
risk factors for early mortality in this population are poorly described. We retrospectively studied cancer patients with clostridial
bacteraemia treated between January 1996 and December 2011. We compared clinical manifestations between patients with solid tumour
and haematological malignancy and assessed risk factors for 7-day mortality. In all, 164 cancer patients developed clostridial bacteraemia
during the study period—85 (52%) with solid tumour and 79 (48%) with haematological malignancy. Common isolates were Clostridium
perfringens (27%), Clostridium septicum (19%) and Clostridium tertium (14%). Solid tumour malignancy patients were more likely to have a focal
gastrointestinal source for bacteraemia and were more likely to undergo subsequent surgery. Haematological malignancy patients were
more often neutropenic and more often had no focal source of bacteraemia. Seven-day mortality was 20% (33/164) and did not vary based
on malignancy type. The adjusted odds ratio of dying within 7 days of clostridial bacteraemia among patients with hypotension (40/164) was
7.2 (95% CI, 2.9–18.1) and in patients with acute haemolysis (7/164) was 10.5 (95% CI, 1.3–85.2). Clostridial species also impacted mortality;
no patient with C. tertium bacteraemia died within 7 days. In conclusion, clinical manifestations of clostridial bacteraemia differed between
patients with solid tumour and haematological malignancy, but 7-day mortality was similar. Patients with hypotension and haemolysis at time
of bacteraemia were at increased risk for early death.
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Introduction
Clostridial bacteraemia is associated with fulminant clinical
illness and high mortality attributed to bacterial toxin produc-
tion [1,2]. However, recent studies have demonstrated that
clostridial bacteraemia infrequently causes a histotoxic syn-
drome, but is often a marker of signiﬁcant gastrointestinal
disease and underlying immunocompromise [3,4]. Despite the
infrequency with which clostridial bacteraemia is associated
with fulminant toxin-mediated illness, associated mortality
ranges from 20% to 48% in adults and may be higher in adults
with malignancy [3–6].
Initial observations linking clostridial bacteraemia and
malignancy date back at least 50 years [1,2]. More recently,
observational studies have supported this association [7–13]; a
recent population-based study demonstrated that risk for
clostridial bacteraemia is signiﬁcantly higher in patients with
cancer [5]. Among cancer patients, clostridial bacteraemia is
typically seen in two distinct groups: patients with solid
tumour malignancy and patients with haematological malig-
nancy (usually acute leukaemia) [1,2,4,14].
Few studies have systematically assessed the clinical char-
acteristics of clostridial bacteraemia in cancer patients [1,2,14].
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The most recent of these, now over 20 years old, reports high
overall associated mortality (42%); Clostridia were frequently
isolated in the context of polymicrobial bacteraemia, which
was associated with further increased risk of death [14].
Because management of solid tumour and haematological
malignancies has changed in the last 20 years, we undertook
this study to characterize clinical manifestations of clostridial
bacteraemia in a recent cohort of cancer patients. Study goals
were to delineate differences in clinical characteristics and
outcomes of patients with solid tumour malignancy and
haematological malignancy with clostridial bacteraemia and
further to determine the risk factors and mortality associated
with clostridial bacteraemia in cancer patients.
Methods
Patients
All adults with malignancy who developed clostridial bacter-
aemia at Dana-Farber Cancer Institute/Brigham and Women’s
Hospital (DFCI/BWH) between 1 January 1996 and 31
December 2011 were included in this analysis. BWH is a
793-bed tertiary care medical centre with approximately
45 000 admissions per year. DFCI, an afﬁliated facility
dedicated to cancer care, has over 320 000 outpatient visits
per year. Inpatient care for DFCI patients occurs at BWH. The
Ofﬁce for Human Research Studies at DFCI/BWH approved
this study.
Patients were identiﬁed by searching the DFCI/BWH
microbiology database for all blood cultures that grew
clostridial species using WHONET software (http://www.
who.int/drugresistance/whonetsoftware/en/ ). Clostridial bac-
teraemia was deﬁned as growth of any clostridial species in
one or more blood culture bottles. Blood cultures were drawn
for assessment of clinical signs or symptoms of infection.
Antibiotic susceptibility of anaerobic isolates was not routinely
tested.
Medical records were reviewed for covariates of interest at
bacteraemia onset including age, gender, malignancy, infection
symptoms (nausea, vomiting, diarrhoea and abdominal pain),
hypotension requiring use of vasopressors, source of bacter-
aemia if identiﬁed, surgical management of infection, absolute
neutrophil count, acute haemolysis, antimicrobials being given
before bacteraemia and in response to bacteraemia, clostridial
species isolated, presence and species of additional isolates for
polymicrobial infections and 7-day mortality. Neutropenia was
deﬁned as absolute neutrophil count <500 cells/mm3. Polymi-
crobial bacteraemia was deﬁned as growth of more than one
bacterial species (including if two different clostridial species
grew) in one or more blood culture bottles drawn on the same
day as the Clostridia spp. grew. Acute haemolysis was deﬁned as
a decline in haemoglobin of >2 g/dL over 24 h or less in
patients without evidence of bleeding and in conjunction with
gross haemolysis seen in blood specimens and/or new indirect
hyperbilirubinaemia of 8 mg/dL or higher.
Clostridia
All blood culture samples were incubated and monitored using
the bioMerieux BacT/ALERT system (bioMerieux Inc., Dur-
ham, NC, USA). Anaerobic gram-positive bacteria that grew
from blood cultures were identiﬁed using the RapID ANA II
panel (Thermo Scientiﬁc, Atlanta, GA, USA).
Statistical analysis
Baseline and infection-related characteristics were initially
compared using two-sided Fisher’s exact test or Wilcoxon
rank sum test where appropriate. Possible predictors of 7-day
mortality identiﬁed on initial analysis were evaluated in a
univariate logistic regression analysis. Only covariates closely
associated with 7-day mortality (p ≤0.05) were included in a
multivariate logistic regression model. Statistical analyses were
performed using SAS version 9.2 (SAS institute, Cary, NC,
USA).
Results
Cohort characteristics and microbiology
During the 16-year study period 164 patients with malignancy
developed clostridial bacteraemia including 85 (52%) with solid
tumour and 79 (48%) with haematological malignancy. Overall
characteristics of the cohort are shown in Table 1. There
were similar numbers of men and women. A substantial
number of patients were neutropenic (42%) and nearly a
quarter had hypotension requiring support with vasopressors
when bacteraemia developed (24%). Seven-day mortality was
20% (33/164). Six patients (4%) presented with clostridial
bacteraemia leading to diagnosis of unrecognized cancer,
including four with solid tumour and two with haematological
malignancy. The rest (158/164, 96%) developed bacteraemia
after cancer treatment was started.
Clostridium perfringens accounted for 44 of 164 episodes of
clostridial bacteraemia (27%) and was the most common
isolate, followed by Clostridium septicum, which caused 31
episodes (19%) and Clostridium tertium, which caused 23
episodes (14%). Many less common clostridial species caused
a substantial proportion of episodes of bacteraemia, as
presented in Table 1. The number of episodes of clostridial
bacteraemia per year in DFCI/BWH patients varied over time.
The median number of episodes was 2.9 per 1000 oncology
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hospital admissions per year between 1998 and 2011 (range
1.8–5.0).
Polymicrobial bacteraemia occurred frequently (61/164,
37%). Most patients with polymicrobial bacteraemia had one
co-pathogen identiﬁed (41/61, 67%) but a third had two or
more co-pathogens identiﬁed (20/61, 33%). Common
co-pathogens were coagulase-negative staphylococci (17 epi-
sodes), Bacteroides spp. (14 episodes), Enterococcus spp. (nine
episodes), Klebsiella spp. (eight episodes) and Escherichia coli
(seven episodes). Among 103 episodes of monomicrobial
bacteraemia, Clostridia spp. was isolated in multiple blood
culture bottles over 48 h in 42 episodes and from one bottle in
61 episodes.
Clinical characteristics by type of malignancy
There were several differences in baseline, clinical and
microbiological characteristics of patients with solid tumour
versus haematological malignancy (Table 1). More patients
with haematological malignancy were male and more were
neutropenic at bacteraemia onset. Patients with solid tumour
malignancy more often had a focal gastrointestinal source of
bacteraemia and more often underwent surgical intervention
after clostridial bacteraemia developed. Patients with haema-
tological malignancy were more likely to be on antibiotics
(typically for empiric treatment of fever and neutropenia)
when clostridial bacteraemia developed.
Clostridial species causing bacteraemia also differed
between the two groups. Speciﬁcally, C. perfringens was the
most common cause of bacteraemia among patients with solid
tumour malignancy (25/85, 29%) and a frequent cause of
bacteraemia among haematological malignancy patients (19/79,
24%). In contrast, C. tertium was the most common cause of
bacteraemia in haematological malignancy patients (23/79,
29%) and caused no infections in patients with solid tumours.
Clostridium septicum was also more common in haematological
malignancy patients (17/79, 22%) than in solid tumour patients
(14/85, 16%).
There were no differences in age, hypotension requiring
vasopressors, haemolysis (only seen in 4% of the cohort),
polymicrobial bacteraemia, or 7-day mortality based on
malignancy type.
Risk factors for 7-day mortality
Clinical factors associated with 7-day mortality were examined
(Table 2). Patients with hypotension requiring vasopressors at
bacteraemia onset were more likely to die within 7 days than
those without hypotension (21/40 vs 12/124, p <0.0001).
Similarly, patients with acute haemolysis when clostridial
Characteristic
Solid tumour
malignancy n = 85
Haematological
malignancy n = 79
Total
n = 164 p value
Male gender 34 (40) 47 (59) 81 (49) 0.02
Median age, years (range) 57 (18–86) 56 (25–87) 57 (18–87) 0.61
Neutropenica 8 (9) 61 (77) 69 (42) <0.0001
Diarrhoea 11 (13) 31 (39) 42 (26) 0.0001
Nausea and vomiting 37 (44) 19 (24) 56 (34) 0.01
Abdominal pain 54 (64) 23 (29) 77 (47) <0.0001
Hypotensionb 19 (22) 21 (27) 40 (24) 0.59
Haemolysis 2 (2) 5 (6) 7 (4) 0.26
Source of bacteraemia
No focal source 13 (15) 44 (56) 57 (35) <0.0001
Focal gastrointestinal sourcec 61 (72) 29 (37) 90 (55)
Other sourced 11 (13) 6 (8) 17 (10)
Skin and soft tissue involvement 2 (2) 4 (5) 6 (4) 0.43
Clostridium species
C. perfringens 25 (29) 19 (24) 44 (27) <0.0001
C. septicum 14 (16) 17 (22) 31 (19)
C. tertium 0 (0) 23 (29) 23 (14)
C. ramosum 9 (11) 3 (4) 12 (7)
C. clostridioforme 7 (8) 3 (4) 10 (6)
C. innocuum 4 (5) 4 (5) 8 (5)
C. paraputriﬁcum 6 (7) 1 (1) 7 (4)
C. cadaveris 2 (2) 1 (1) 3 (2)
C. subterminale 3 (4) 1 (1) 4 (2)
C. hastiforme 3 (4) 0 (0) 3 (2)
Otherse 12 (14) 7 (9) 19 (12)
Polymicrobial bacteraemia 35 (41) 26 (33) 61 (37) 0.33
Surgical intervention 21 (25) 7 (9) 28 (17) 0.007
Antibiotics before bacteraemiaf 10 (12) 43 (54) 53 (32) <0.0001
7-day mortality 19 (22) 14 (18) 33 (20) 0.56
aDeﬁned as an absolute neutrophil count <500 cells/mm3 at the time of bacteraemia.
bRequiring the use of supportive vasopressors.
cIncludes: enteric perforation, peritoneal or liver abscess, solid tumour-enteric ﬁstula, colitis or typhlitis, biliary
obstruction, or incarcerated hernia.
dIncludes: urinary obstruction, urinary tract infection, bladder perforation, graft-versus-host disease, genital herpes
simplex virus, anal erosions, gluteus medius haematoma, severe skin burn.
eC. acetobutylicum (2), C. bifermentans (3), C. butyricum (1), C. novyi (1), C. sartagoforme (1), C. sporogenes (1), C. sordelli (1),
unspeciﬁed clostridial species (9).
fDeﬁned as patients on systemic antibiotics for other indications up to 24 h before the development of bacteraemia.
TABLE 1. Baseline and infection
related characteristics compared by
type of malignancy
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 752–757
754 Clinical Microbiology and Infection, Volume 20 Number 8, August 2014 CMI
bacteraemia was diagnosed were more likely to die within
7 days than those without haemolysis (5/7 vs 28/157, p 0.004).
Symptoms at onset of bacteraemia were also associated with
7-day mortality. Speciﬁcally 7-day mortality was higher among
patients with nausea and vomiting than those without these
symptoms (17/56 vs 16/108, p 0.02) and there was a trend
towards increased mortality among those who presented with
abdominal pain compared with those who did not.
The clostridial species causing the bacteraemia was also
associated with 7-day mortality (Table 2). Speciﬁcally, no
patients with C. tertium bacteraemia died within 7 days com-
pared with those who were bacteraemic with other Clostridia
(0/23 vs 33/141, p 0.005). The proportion of patients with
C. septicum and C. ramosum bacteraemia was higher among
those who died within 7 days than those who did not (24% vs
16%; 12% vs 6%, respectively). There was a trend towards
increased 7-day mortality in patients with polymicrobial versus
monomicrobial bacteraemia.
Logistic regression modelling was performed to assess risk
factors for 7-day mortality (Table 3). Clostridial species were
not included in the regression because no patients with
C. tertium bacteraemia died within 7 days, but C. septicum
(which appeared to be associated with increased mortality)
was included. In univariate analysis nausea and vomiting,
hypotension, acute haemolysis and focal gastrointestinal
source of bacteraemia were associated with increased 7-day
mortality. In multivariate analysis only hypotension and acute
haemolysis were independently associated with 7-day mortal-
ity. The odds ratio of dying within 7 days of clostridial
bacteraemia for patients with hypotension was 7.23 (95% CI
2.90–18.06) and for patients with acute haemolysis was 10.53
(95% CI 1.30–85.17).
TABLE 2. Baseline and infec-
tion-related characteristics com-
pared by 7-day mortality
Characteristic
Died ≤7 days
n = 33
Survived >7 days
n = 131
Total
n = 164 p value
Male gender 14 (42) 67 (51) 81 (49) 0.44
Median age, years (range) 62 (20–83) 56 (18–87) 57 (18–87) 0.29
Haematological malignancy 14 (42) 65 (50) 79 (48) 0.56
Acute leukaemia or myelodysplasia 11 (33) 46 (35) 57 (35)
Chronic leukaemia 1 (3) 6 (5) 7 (4)
Lymphoma and myeloma 2 (6) 13 (10) 15 (9)
Solid tumour malignancy 19 (58) 66 (50) 85 (52)
Colorectal cancer 5 (15) 13 (10) 18 (11)
Gynaecological cancera 3 (9) 16 (12) 19 (12)
Other gastrointestinal cancerb 4 (12) 13 (10) 17 (10)
Sarcoma 3 (9) 10 (8) 13 (8)
Male genitourinary cancerc 0 (0) 7 (5) 7 (4)
Other cancer typed 4 (12) 7 (5) 11 (7)
Neutropenic 13 (39) 56 (43) 69 (42) 0.84
Diarrhoea 9 (27) 33 (25) 42 (26) 0.83
Nausea and vomiting 17 (52) 39 (30) 56 (34) 0.02
Abdominal pain 20 (56) 57 (44) 77 (47) 0.08
Hypotension 21 (64) 19 (15) 40 (24) <0.0001
Haemolysis 5 (15) 2 (2) 7 (4) 0.004
Source of bacteraemia
No focal source 8 (24) 49 (37) 57 (35) 0.07
Focal gastrointestinal source 24 (73) 66 (50) 90 (55)
Other sourcee 1 (2) 16 (12) 17 (10)
Skin and soft tissue involvement 2 (6) 4 (3) 6 (4) 0.35
Clostridium species
C. perfringens 9 (27) 35 (27) 44 (27) 0.10
C. septicum 8 (24) 23 (16) 31 (19)
C. tertium 0 (0) 23 (18) 23 (14)
C. ramosum 4 (12) 8 (6) 12 (7)
C. clostridioforme 3 (9) 7 (5) 10 (6)
C. innocuum 3 (9) 5 (4) 8 (5)
C. paraputriﬁcum 2 (6) 5 (4) 7 (4)
C. cadaveris 1 (3) 2 (2) 3 (2)
C. subterminale 0 (0) 4 (3) 4 (3)
C. hastiforme 0 (0) 3 (2) 3 (2)
Othersf 3 (9) 16 (12) 19 (12)
Polymicrobial bacteraemia 17 (48) 44 (34) 61 (37) 0.07
Surgical intervention 4 (12) 24 (18) 28 (17) 0.60
Antibiotics before bacteraemiag 10 (30) 43 (33) 53 (32) 0.84
Penicillin or clindamycin within 48 hh 11 (33) 34 (26) 45 (27) 0.39
Active antibiotic within 48 hi 31 (94) 108 (82) 139 (85) 0.17
aIncludes ovarian, cervical and endometrial cancer.
bIncludes pancreatic cancer, cholangiocarcinoma.
cIncludes testicular and prostate cancer.
dIncludes laryngeal cancer (1), breast cancer (3), lung cancer (2), bladder cancer (1), renal cell carcinoma (2), Merkel cell
carcinoma (1), melanoma (1).
eIncludes: urinary obstruction, urinary tract infection, bladder perforation, graft-versus-host disease, genital herpes
simplex virus, anal erosions, gluteus medius haematoma, severe skin burn.
fC. acetobutylicum (2), C. bifermentans (3), C. butyricum (1), C. novyi (1), C. sartagoforme (1), C. sporogenes (1), C. sordelli (1),
unspeciﬁed clostridial species (9).
gDeﬁned as patients on systemic antibiotics for other indications up to 24 h before the development of bacteraemia.
hTreatment given within 48 h of bacteraemia onset; penicillins included penicillin G, mezlocillin, ampicillin, or piperacillin.
iTreatment one or more of the following agents within 48 h of bacteraemia onset: penicillin G, mezlocillin, ampicillin,
piperacillin, clindamycin, metronidazole, vancomycin and carbapenems.
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Antimicrobial treatment
Within 48 h of clostridial bacteraemia 45 of 164 patients (27%)
were treated with a penicillin (penicillin G, mezlocillin,
ampicillin or piperacillin) or clindamycin and 139 (85%) were
treated with at least one antimicrobial agent with in vitro
activity against most Clostridia including penicillins, clindamycin,
metronidazole, vancomycin or carbapenems [3,4,15–17].
Among the 25 patients who were not treated with an active
antibiotic within 48 h, eight were treated with one or more
antibiotics that are not typically active in vitro against Clostridia
(ceftazidime, gentamicin, levoﬂoxacin, ciproﬂoxacin) during the
ﬁrst 48 h, six were not treated with antibiotics (two of whom
chose comfort-focused medical care only), and the remainder
started active antibiotics more than 48 h after bacteraemia had
developed. There was no association between 7-day mortality
and treatment with penicillin or clindamycin within 48 h nor
was there an association between 7-day mortality and
treatment with any antimicrobial agents with in vitro activity
against Clostridia (Table 2).
The relationship between 7-day mortality and antibiotic
treatment was also assessed for episodes of bacteraemia
caused by the two most common isolates, C. perfringens and
C. septicum. Together, these clostridial species caused 46%
(75/164) of bacteraemias in the cohort. The majority (69/75,
92%) were treated with two or more antibiotics in the ﬁrst
48 h, including at least one agent active in vitro against Clostridia
(as above). As with the entire cohort, there was no association
between 7-day mortality and treatment with penicillins or
clindamycin within 48 h, nor was there an association between
7-day mortality and treatment with at least one of the active
agents (as above) within 48 h of bacteraemia.
Discussion
In this large cohort of cancer patients with clostridial
bacteraemia we found several important differences in clinical
characteristics of patients with haematological and solid
tumour malignancies. Solid tumour patients were more likely
to have a focal gastrointestinal abnormality as the source of
bacteraemia and more often underwent a surgical procedure
to correct the abnormality. In contrast, patients with haema-
tological malignancy were more often neutropenic and more
likely to be on antibiotics at bacteraemia onset, usually for
empiric treatment of fever and neutropenia. There was also a
difference in clostridial species that caused bacteraemia in
these groups. While C. perfrigens, C. septicum and C. tertium
accounted for 75% of isolates in patients with haematological
malignancies, there was a greater diversity of clostridial species
seen among solid tumour malignancy patients.
Despite these differences, there was no difference in the
7-day mortality between patients with haematological and solid
tumour malignancies. Seven-day mortality in the entire cohort,
20%, is lower than the greater than 50% mortality reported in
cancer patients in other studies [6,14]. Similar to an older
study of clostridial bacteraemia in cancer patients, hypotension
was an independent risk factor for death within 7 days [14].
Though it seems likely that initiation of appropriate
antibiotics in a timely fashion impacts early mortality from
clostridial bacteraemia (at least one study has suggested this
[6]), no particular antibiotic regimen in the ﬁrst 48 h of
bacteraemia conferred a 7-day survival beneﬁt in the entire
cohort or when assessed among C. perfringens and C. septicum
speciﬁcally. However, this conclusion is limited by the small
number of patients in this cohort who did not receive an active
antibiotic during the ﬁrst 48 h after bacteraemia had devel-
oped (15%). Most studies assessing the antibiotic susceptibility
of Clostridia have shown that most species, except C. tertium,
are susceptible to penicillin, metronidazole, carbapenems and
vancomycin [3–5,15–17]. This large number of active antibi-
otics is probably the reason that the large majority of patient in
this cohort were treated empirically with an active antibiotic
within 48 h of bacteraemia. An additional issue complicating
interpretation of antibiotic impact on 7-day mortality in this
study is the frequency of polymicrobial bacteraemia with other
enteric pathogens that require speciﬁc antimicrobial therapy
and confer their own associated risk of death.
Clostridium septicum was the second most common cause of
bacteraemia in this cohort after C. perfringens, as has been
observed in other cohorts [5,14]. Several previous publications
Characteristic
Univariate odds
ratio (95% CI) p value
Multivariate odds
ratio (95% CI) p value
Nausea and vomiting 2.51 (1.15–5.46) 0.02 2.14 (0.85–5.38) 0.10
Abdominal pain 2.00 (0.92–4.35) 0.08 – –
Hypotension 10.32 (4.37–24.37) <0.0001 7.23 (2.90–18.06) <0.0001
Haemolysis 11.52 (2.13–62.41) 0.005 10.53 (1.30–85.17) <0.0001
Focal gastrointestinal source
of bacteraemia
2.63 (1.14–6.08) 0.02 2.01 (0.70–5.78) 0.19
Clostridium septicum 1.50 (0.60–3.75) 0.38 – –
Polymicrobial bacteraemia 2.10 (0.97–4.55) 0.06 – –
TABLE 3. Logistic regression of
7-day mortality
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have observed an association between this pathogen and
severe clinical illness and death in cancer patients [8–10]. The
virulence of C. septicum is typically attributed to a-toxin
production, which can cause rapid tissue invasion and haem-
olysin production, which can infrequently cause intravascular
haemolysis [8,9].
In contrast, C. tertium bacteraemia was seen exclusively in
patients with haematological malignancy in this cohort and was
the most common cause of clostridial bacteraemia in this
patient group. No patients with C. tertium bacteraemia died
within 7 days. Unlike other clostridial species, C. tertium is
aerotolerant and does not produce toxins [7,11,13]. Clinically it
has been associated with mild clinical illness in patients with
chemotherapy-induced neutropenia and related intestinal
mucosal injury, as was seen in this cohort [7,11–13]. All
patients in this cohort with C. tertium bacteraemia had under-
lying acute leukaemia and all were on a third- or fourth-gen-
eration cephalosporin for empirical treatment of fever and
neutropenia when bacteraemia developed. Other studies have
suggested that broad-spectrum cephalosporins, ceftazidime in
particular, may select for this organism, which can be resistant
to some b-lactams, metronidazole and clindamycin [7,11].
Notably, older studies considered isolated clostridial bac-
teraemia in the absence of a focal infection to be a contaminant
[4]. A potential limitation of this study is that some episodes of
clostridial bacteraemia included could have been due to blood
culture contamination. However, this is unlikely for several
reasons. First, all blood cultures were drawn for symptoms of
infection. Second over 40% of patients in this cohort were
neutropenic. Clostridial bacteraemia with lack of focal site of
infection in the context of fever and neutropenia suggests
pathogenic translocation of bacteria from the gastrointestinal
tract, not contamination, similar to enteric gram-negative
bacteria in this setting.
In conclusion, in this large cohort of cancer patients with
clostridial bacteraemia we found several important differences
in the clinical characteristics of patients with haematological
malignancy compared with those with solid tumour malig-
nancy, but mortality was similar. Hypotension and haemolysis,
both of which have historically been associated with poor
outcomes, remain independent risk factors for early mortality
in this population. Clostridium tertium was exclusively seen in
patients with haematological malignancy and was associated
with no mortality.
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